par Loi, Sherene
;Sirtaine, Nicolas;Piette, Fanny;Salgado, Roberto;Viale, Giuseppe;Van Eenoo, Françoise;Rouas, Ghizlane;Francis, Prudence;Crown, John P A;Hitre, Erika;de Azambuja, Evandro
;Quinaux, Emmanuel;Di Leo, Angelo
;Michiels, Stefan
;Piccart-Gebhart, Martine
;Sotiriou, Christos 
Référence Journal of clinical oncology, 31, 7, page (860-867)
Publication Publié, 2013-03






Référence Journal of clinical oncology, 31, 7, page (860-867)
Publication Publié, 2013-03
Article révisé par les pairs
Résumé : | Previous preclinical and clinical data suggest that the immune system influences prognosis and response to chemotherapy (CT); however, clinical relevance has yet to be established in breast cancer (BC). We hypothesized that increased lymphocytic infiltration would be associated with good prognosis and benefit from immunogenic CT-in this case, anthracycline-only CT-in selected BC subtypes. |